Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salmeterol/fluticasone in stable COPD assessed by exhaled breath condensate inflammatory markers
ChiCTR-ONC-12002052Phase 4Completed
- Sponsor
- Shenzhen Nanshan People's Hospital
- Start
- Feb 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of salmeterol and fluticasone in chronic obstructive pulmonary disease (COPD), sponsored by Shenzhen Nanshan People's Hospital. Primary endpoint: Exhaled breath condensate inflammatory markers. Started Feb 2011; status: completed.
02
Drugs
salmeterolfluticasone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ChiCTR-ONC-12002052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-12002052.